Trial Profile
A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Vibostolimab (Primary) ; Vibostolimab+pembrolizumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms KEYVIBE-001; MK-7684-001
- Sponsors Merck Sharp & Dohme
- 12 Feb 2024 Planned End Date changed from 24 Jan 2025 to 31 Oct 2024.
- 12 Feb 2024 Planned primary completion date changed from 24 Jan 2025 to 31 Oct 2024.
- 02 Jul 2022 Results (n=27) reporting safety and efficacy in patients with advanced gastric cancer presented at the 24th World Congress on Gastrointestinal Cancer